These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37176525)

  • 1. Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine.
    Ohnewein B; Shomanova Z; Paar V; Topf A; Jirak P; Fiedler L; Granitz C; Van Almsick V; Semo D; Zagidullin N; Dieplinger AM; Sindermann J; Reinecke H; Hoppe UC; Pistulli R; Motloch LJ
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study.
    Koçak A; Aydin S; Alibaşiç H; Çiçek M; Ekici B
    Medicine (Baltimore); 2023 Oct; 102(43):e35589. PubMed ID: 37904474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.
    Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S
    JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
    Okutucu S; Fatihoglu SG; Sabanoglu C; Bursa N; Sayin BY; Aksoy H; Oto A
    Herz; 2021 Apr; 46(Suppl 1):69-74. PubMed ID: 31796977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
    Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
    ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system.
    Kim BJ; Huang CW; Chung J; Neyer JR; Liang B; Yu AS; Kwong EK; Park JS; Hung P; Sim JJ
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1173-1179. PubMed ID: 36125061
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
    Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
    Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis.
    Jariwala P; Punjani A; Boorugu H; Madhawar DB
    Indian Heart J; 2021; 73(2):211-213. PubMed ID: 33865520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
    Vasquez N; Carter S; Grodin JL
    Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.